Hannah Clarke

"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.

"Our recommendation is to adopt a Mediterranean diet enlisting the help of a dietician, because people absorb nutrients in different ways, depending on the food, the digestive system, the person’s genotype and possibly their microbiome," says Permal Deo, MD.

"Our hope is that this study, and others, will encourage a review of the levels of nitrate that are allowed in water, in order to ensure that there is no risk to human health,” said Carolina Donat-Vargas, PhD, MPH.

"This year's Summit was one of the biggest and most exciting so far," says Kevin Koo, MD, MPH.

Once patients had a PSA level of 0.25 ng/mL or higher, the risk of mortality increased by approximately 50%.

The investigators retrospectively analyzed ABU case log data on 8 different BPH surgical procedures ranging from 2008 to 2021.

"Increasing regulation, excess bureaucracy, decreasing autonomy, declining reimbursement, and increased administrative burdens are all increasing the risk of burnout," says Andrew M. Harris, MD.

"[Although] American Indian/Alaskan Native patients do present with more advanced prostate cancer, show lower rates of definitive treatment, and higher mortality, once we adjust for some of these disparities in access, we found that there were no significant differences in mortality," says Carissa E. Chu, MD.

"The Medicaid and uninsured patients had significantly lower odds of getting treatment than those who [have] private insurance," says Madison Novosel, BA.

At 6 months, high-grade RFS in the BCG group was 76%, compared with 92% in the gemcitabine and docetaxel group.

Immunotherapy utilization and costs accounted for 84% of the net increase in Medicare Part B payments, yet the treatment was administered to fewer than 20% of patients.

"We found a sizeable and statistically significant uptick in compliance with genetic testing and compliance with post-test genetic counseling in patients who underwent testing after the implementation of the standardized protocol," says Siddharth Ramanathan.

Barrigel is a hyaluronic acid rectal spacer indicated for patients with T1 to T3b prostate cancer disease.

Black race was identified as an independent predictor of 30-day readmission even after investigators controlled for differences in patient demographics, clinical factors, and comorbidities.

"It's important to make sure that this is something that is desired by our patients before pursuing further," says Timothy D. Lyon, MD, FACS.

"I gave a summary of what we have developed in our program in Houston at Baylor College of Medicine using what we designated as a resident wellness curriculum," said Jennifer M. Taylor, MD, MPH.

The findings also highlighted the diversity of physicians performing the procedure in regard to background and outcomes.

"The test is fast, minimally invasive, and cost-effective, and opens up a new suite of tools that will help us optimize treatment and quality of life for prostate cancer patients,” said Edwin Posadas, MD.

The device has the ability to monitor intrarenal pressure (IRP) in real-time during kidney stone procedures.

Lerapolturev will be given via intravesicular instillation to adult patients with recurrent NMIBC intended for transurethral resection of bladder tumor (TURBT) or cystectomy.

“Where we really need to see change is talking about what the patient wants, what they're worried about, and what would work best for them,” says Angela Fagerlin, PhD.

“If there is such a clear difference between what different physicians are recommending, that calls into the need for patients to be more involved in decisions,” says Angela Fagerlin, PhD.

"I think it's important to realize we're not one-dimensional, that even if we have our day job as urologists, a lot of these things affect us," says Diana Londoño, MD.

"I think what you're going to see is more of the urologic end points, the different cancers, especially prostate cancer," says Mark Moyad, MD, MPH.

"We noted in our overall population, which was about 214 women, there was a 40% discontinuation rate for Botox treatments in the office," says Katherine L. Woodburn, MD.

FACT-RNT is the first tool to measure patient reported outcomes associated with radionuclide therapy for prostate cancer.

The spray is a liquid suspension of sildenafil citrate administered orally via a spray pump.

The study considered 4 dimensions of the workplace: equal access, work-life balance, freedom from gender bias, and supportive leadership.

"Last year was a year of many changes socially within the United States. Some of those changes stirred up a lot of interest, enthusiasm, and energy for trying to direct our community toward positive change," said Manoj Monga, MD, FACS.

“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.